Aptevo Therapeutics is a clinical-stage biotech company focused on bringing novel immuno-oncology therapeutics to market. Aptevo's lead clinical candidate and preclinical candidates were developed based on the Company's versatile and robust ADAPTIR(TM) modular protein technology platform. The ADAPTIR platform is capable of generating highly differentiated bispecific antibodies with unique mechanisms of action for the treatment of different types of cancer.